Avelumab With Chemoradiation in Locally Advanced Rectal Cancer

Rectal Cancer Clinical Trial

Official title:

Phase II Trial PD-L1/PD-1 Blockade Avelumab (MSB0010718C) With Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03299660
• Other study ID #: AveRec
• Status: Completed
• Phase: Phase 2
• Start date: April 30, 2018
• Est. completion date: February 28, 2023

Study information

• Verified date: March 2023
• Source: Peter MacCallum Cancer Centre, Australia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer. It is hypothesised that this may enhance the pathological and imaging response rates whilst potentially reducing the relapse rates. Participants will receive standard long course chemoradiotherapy (LCCRT) treatment with radiotherapy and 5-fluorouracil (5 FU)/Capecitabine for 6 weeks, this then followed by 4 cycles of Avelumab and then surgical resection. The trial will measure disease response just prior to surgery and participants will be followed up for a minimum of 18 months (from study entry) and up to 42 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female aged = 18 years at screening

2. Patients with histologically confirmed rectal adenocarcinoma clinical stage T3bN1-N2M0, T3c/dN0-N2M0, T4N0-N2M0 (see Appendix 1),1 as defined by pelvic MRI

3. Planned to receive neoadjuvant long course chemoradiotherapy (50.4 Gy, with infusional 5FU or capecitabine) followed by curative total mesorectal excision plus abdomino-perineal resection or anterior resection

4. Lower border of tumour must be within 12 cm from anal verge

5. Measurable disease by RECIST1.12

6. ECOG Performance Status 0-1

7. Patients must be willing to provide fresh (where possible) and archival tumour tissue samples for translational studies at specified time points

8. Adequate organ function

1. Absolute neutrophil count =1.5 x 109/L

2. Platelet count =100 x 109/L

3. Haemoglobin = 90 g/L (may have been transfused)

4. Creatinine = 1.5 x upper normal limit OR measured creatinine clearance = 50 mL/minute

5. Total bilirubin = 1.5 x upper normal limit

6. AST/ALT = 2.5 x upper normal limit

9. Female patients of childbearing potential must have a negative urine or serum pregnancy test at screening

10. Both male and female patients should be willing to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) if the risk of conception exists

11. Has provided written informed consent for the trial

12. Agrees to comply with trial therapy or trial-related investigations and evaluations

Exclusion Criteria:

1. Patients with disease outside the pelvis

2. Prior pelvic radiotherapy

3. Participation in another interventional clinical trial within 30 days of registration (participation in observational studies are permitted)

4. Concurrent anti-cancer treatment

5. Concurrent treatment with a non-permitted drug (Section 8.3.2)

6. Major surgery for any reason within 4 weeks of registration (except defunctioning stoma creation with the patient having fully recovered from this procedure)

7. Current use of immunosuppressive medication. Except for the following: (a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); (b). Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; (c). Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication); (d) Short-term administration of systemic steroids (that is, for allergic reactions or the management of irAEs) is allowed while on study. Note: Patients receiving bisphosphonate or denosumab are eligible

8. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible

9. Active or history of immunodeficiencies

10. Has received prior therapy with an anti-PD1, anti-PDL1, anti-PDL2 or anti-CTLA-4 agents

11. Has clinically significant (that is, active) cardiovascular disease: cerebral vascular accident / stroke (< 6 months prior to registration), myocardial infarction (< 6 months prior to registration), unstable angina, congestive heart failure (New York Heart Association Classification Class = II), or serious cardiac arrhythmia requiring medication.

12. Has an active infection requiring systemic therapy

13. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study

14. Prior malignancies within 3 years of registration (with the exception of non- melanomatous skin cancer)

15. Prior organ transplantation, including allogeneic stem-cell transplantation

16. A known history of testing positive for HIV or known acquired immunodeficiency syndrome (AIDS)

17. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test is positive)

18. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (CTCAE v4.03 grade = 3)

19. Is pregnant or lactating

20. Vaccination within 4 weeks of registration and while on trials is prohibited except for administration of inactivated vaccines

21. Known deficiency of dihydropyrimidine dehydrogenase

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• Avelumab
Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
• 5 Fluorouracil
5FU continuous infusion 225mg/m2/day during radiotherapy
• Capecitabine Pill
Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy

Radiation:
• Radiotherapy
50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week

Procedure:
• Surgical Resection
Surgical resection of tumour mass post radiotherapy and chemotherapy

Locations

Country	Name	City	State
Australia	Box Hill Hospital	Box hill	Victoria
Australia	Cabrini Hospital	Malvern	Victoria
Australia	Monash Health	Melbourne	Victoria
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	Alfred Hospital	Prahran	Victoria
Australia	Prince of Wales Hospital	Randwick	New South Wales
Australia	Royal North Shore	St Leonards	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Peter MacCallum Cancer Centre, Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological Response rate	To investigate the role of PD-L1 blockade for rectal cancer following neoadjuvant LCCRT, prior to definitive surgical resection, in terms pathological response rates. Assessed by tumour regression grade in resected rectal cancers post LCCRT at the time of definitive surgery: according to Ryan et al	At time of resection i.e.16 -18 weeks post commencement of treatment
Secondary	Response as per structural imaging	Describe radiological response rate based on Pelvic MRI post PD-L1 blockade as per RECIST 1.1	At 8 weeks post LCCRT
Secondary	Overall FDG PET response	Describe FDG-PET response rate post PDL1 blockade as per PERCIST	At 8 weeks post LCCRT
Secondary	Define toxicity during administration of PDL1 inhibitor and post-surgery	Worst grade AE's and SAE's CTCAE version 4.03	From consent until 4 weeks post surgery
Secondary	Determine rate of downstaging	Patients will be considered downstaged if the pathologic T or N stage at surgery assessment is lower than the initial radiological stage.	At time of surgical resection